Riku Rautsola, President and CEO of VIRxSYS, participated in a special session on HIV at the American Public Health Association (APHA) Annual Meeting & Exposition this week. The APHA Annual Meeting & Exposition is the principal congregation for public health professionals to learn about and share cutting edge research, exceptional practices, and innovative products and services. It is the largest and oldest gathering of public health professionals in the world, with more than 13,000 specialists from around the world. The goal of the APHA Annual Meeting & Exposition is to addresses current and emerging health science, policy, and practice issues in an effort to prevent disease and promote health. With over 30 million people living with HIV worldwide, there is an urgent need to decrease incidence and prevalence of the disease by reducing transmission and develop lower-cost treatments. In response, this year a special session explored factors related to HIV treatment issues, providing the opportunity to understand issues related to HIV development and research in the context of the epidemic today. Dr. Rautsola presented information on VRX1273, the therapeutic and preventative vaccine, being developed by VIRxSYS. VIRxSYS believes that VRX1273 vaccine has the potential to be a functional cure for HIV, with reduced cost and toxicity compared to existing treatments. VIRxSYS is honored to be invited to present at the APHA Annual Meeting.